Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 325 to 328 of 328 entries
Sorted by: Best Match Show Resources per page
Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B.
PMID: 34380976
J Immunother. 2021 Oct 01;44(8):325-334. doi: 10.1097/CJI.0000000000000383.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the management of advanced malignancies but are associated with diarrhea and colitis. The objective of our systematic review and meta-analysis was to determine the incidence and outcomes of ICI-associated diarrhea and colitis....

Cite
Tran AN, Wang M, Hundt M, et al. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. J Immunother. 2021;44(8):325-334doi: 10.1097/CJI.0000000000000383.
Tran, A. N., Wang, M., Hundt, M., Chugh, R., Ohm, J., Grimshaw, A., Ciarleglio, M., Hung, K. W., Proctor, D. D., Price, C. C., Laine, L., & Al-Bawardy, B. (2021). Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal of immunotherapy (Hagerstown, Md. : 1997), 44(8), 325-334. https://doi.org/10.1097/CJI.0000000000000383
Tran, Ashley N, et al. "Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 44,8 (2021): 325-334. doi: https://doi.org/10.1097/CJI.0000000000000383
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. J Immunother. 2021 Oct 01;44(8):325-334. doi: 10.1097/CJI.0000000000000383. PMID: 34380976.
Copy Download .nbib Format: NLM
Biallelic variants in RNU12 cause CDAGS syndrome.

Human mutation

Xing C, Kanchwala M, Rios JJ, Hyatt T, Wang RC, Tran A, Dougherty I, Tovar-Garza A, Purnadi C, Kumar MG, Berk D, Shinawi M, Irvine AD, Toledo-Bahena M, Agim NG, Glass DA.
PMID: 34085356
Hum Mutat. 2021 Aug;42(8):1042-1052. doi: 10.1002/humu.24239. Epub 2021 Jun 15.

CDAGS Syndrome is a rare congenital disorder characterized by Craniosynostosis, Delayed closure of the fontanelles, cranial defects, clavicular hypoplasia, Anal and Genitourinary malformations, and Skin manifestations. We performed whole exome and Sanger sequencing to identify the underlying molecular cause...

Cite
Xing C, Kanchwala M, Rios JJ, et al. Biallelic variants in RNU12 cause CDAGS syndrome. Hum Mutat. 2021;42(8):1042-1052doi: 10.1002/humu.24239.
Xing, C., Kanchwala, M., Rios, J. J., Hyatt, T., Wang, R. C., Tran, A., Dougherty, I., Tovar-Garza, A., Purnadi, C., Kumar, M. G., Berk, D., Shinawi, M., Irvine, A. D., Toledo-Bahena, M., Agim, N. G., & Glass, D. A. (2021). Biallelic variants in RNU12 cause CDAGS syndrome. Human mutation, 42(8), 1042-1052. https://doi.org/10.1002/humu.24239
Xing, Chao, et al. "Biallelic variants in RNU12 cause CDAGS syndrome." Human mutation vol. 42,8 (2021): 1042-1052. doi: https://doi.org/10.1002/humu.24239
Xing C, Kanchwala M, Rios JJ, Hyatt T, Wang RC, Tran A, Dougherty I, Tovar-Garza A, Purnadi C, Kumar MG, Berk D, Shinawi M, Irvine AD, Toledo-Bahena M, Agim NG, Glass DA. Biallelic variants in RNU12 cause CDAGS syndrome. Hum Mutat. 2021 Aug;42(8):1042-1052. doi: 10.1002/humu.24239. Epub 2021 Jun 15. PMID: 34085356.
Copy Download .nbib Format: NLM
The concentration and health risk assessment of radionuclides in the muscle of tuna fish: A worldwide systematic review and meta-analysis.

Chemosphere

Fakhri Y, Sarafraz M, Pilevar Z, Daraei H, Rahimizadeh A, Kazemi S, Khedher KM, Thai VN, Ba LH, Mousavi Khaneghah A.
PMID: 34871618
Chemosphere. 2021 Dec 03;289:133149. doi: 10.1016/j.chemosphere.2021.133149. Epub 2021 Dec 03.

Exposure to radionuclides, especially in food, can endanger the health of consumers. In this study, a systematic review and meta-analysis were performed regarding the concentration of radionuclides in tuna fish muscle. International databases including PubMed, Scopus, and Embase were...

Cite
Fakhri Y, Sarafraz M, Pilevar Z, et al. The concentration and health risk assessment of radionuclides in the muscle of tuna fish: A worldwide systematic review and meta-analysis. Chemosphere. 2021;289:133149doi: 10.1016/j.chemosphere.2021.133149.
Fakhri, Y., Sarafraz, M., Pilevar, Z., Daraei, H., Rahimizadeh, A., Kazemi, S., Khedher, K. M., Thai, V. N., Ba, L. H., & Mousavi Khaneghah, A. (2021). The concentration and health risk assessment of radionuclides in the muscle of tuna fish: A worldwide systematic review and meta-analysis. Chemosphere, 289133149. https://doi.org/10.1016/j.chemosphere.2021.133149
Fakhri, Yadolah, et al. "The concentration and health risk assessment of radionuclides in the muscle of tuna fish: A worldwide systematic review and meta-analysis." Chemosphere vol. 289 (2021): 133149. doi: https://doi.org/10.1016/j.chemosphere.2021.133149
Fakhri Y, Sarafraz M, Pilevar Z, Daraei H, Rahimizadeh A, Kazemi S, Khedher KM, Thai VN, Ba LH, Mousavi Khaneghah A. The concentration and health risk assessment of radionuclides in the muscle of tuna fish: A worldwide systematic review and meta-analysis. Chemosphere. 2021 Dec 03;289:133149. doi: 10.1016/j.chemosphere.2021.133149. Epub 2021 Dec 03. PMID: 34871618.
Copy Download .nbib Format: NLM
Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease.

Pharmaceutics

Castro-Suárez N, Trame MN, Ramos-Suzarte M, Dávalos JM, Bacallao-Mendez RA, Maceo-Sinabele AR, Mangas-Sanjuán V, Reynaldo-Fernández G, Rodríguez-Vera L.
PMID: 33256255
Pharmaceutics. 2020 Nov 26;12(12). doi: 10.3390/pharmaceutics12121147.

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a...

Cite
Castro-Suárez N, Trame MN, Ramos-Suzarte M, et al. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics. 2020;12(12)doi: 10.3390/pharmaceutics12121147.
Castro-Suárez, N., Trame, M. N., Ramos-Suzarte, M., Dávalos, J. M., Bacallao-Mendez, R. A., Maceo-Sinabele, A. R., Mangas-Sanjuán, V., Reynaldo-Fernández, G., & Rodríguez-Vera, L. (2020). Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics, 12(12), . https://doi.org/10.3390/pharmaceutics12121147
Castro-Suárez, Niurys de, et al. "Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease." Pharmaceutics vol. 12,12 (2020). doi: https://doi.org/10.3390/pharmaceutics12121147
Castro-Suárez N, Trame MN, Ramos-Suzarte M, Dávalos JM, Bacallao-Mendez RA, Maceo-Sinabele AR, Mangas-Sanjuán V, Reynaldo-Fernández G, Rodríguez-Vera L. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics. 2020 Nov 26;12(12). doi: 10.3390/pharmaceutics12121147. PMID: 33256255; PMCID: PMC7760646.
Copy Download .nbib Format: NLM
Showing 325 to 328 of 328 entries